Valuation: Compass Therapeutics, Inc.

Market Cap 330M 287M 272M 247M 461M 31.56B 463M 3.24B 1.25B 16.04B 1.24B 1.21B 51.35B P/E 2026 *
-3.66x
P/E 2027 * -3.31x
Enterprise Value 180M 156M 148M 134M 251M 17.2B 252M 1.76B 682M 8.74B 675M 660M 27.98B EV / Sales 2026 *
-
EV / Sales 2027 * 8.78x
Free-Float
87.55%
Yield 2026 *
-
Yield 2027 * -
1 day+2.19%
1 week-8.78%
Current month-21.76%
1 month-19.05%
3 months-8.78%
6 months-65.69%
Current year-65.18%
1 week 1.8
Extreme 1.8
2.09
1 month 1.8
Extreme 1.8
2.55
Current year 1.61
Extreme 1.61
6.88
1 year 1.61
Extreme 1.61
6.88
3 years 0.76
Extreme 0.765
6.88
5 years 0.76
Extreme 0.765
6.88
10 years 0.76
Extreme 0.765
11
Manager TitleAgeSince
Chief Executive Officer 65 28/05/2024
Director of Finance/CFO 54 09/12/2024
Chief Tech/Sci/R&D Officer 50 01/01/2026
Director TitleAgeSince
Director/Board Member 65 01/01/2014
Director/Board Member 64 01/01/2015
Chairman 61 01/01/2015
Date Insider Type Main position Quantity % Market Cap. Importance
4/29/26 A Buy

Controller/Auditor

15,000 0.0083%
4/29/26 A Buy

General Counsel

25,000 0.0139%
4/29/26 A Free

Controller/Auditor

15,000 0.0083%
Change 5-day change 1-year change 3-year change Capi.($)
+1.37%-8.78%-46.72%-9.22% 330M
+1.76%+3.62%+49.92%+101.12% 69.69B
+2.29%+0.32%+37.65%+77.03% 61.24B
+1.15%-3.18%-14.88%+364.14% 26.77B
+0.32%+2.58%+29.26%+14.12% 26.12B
+3.02%+2.16%+0.34%-9.68% 24.07B
+1.49%+7.73%+26.85%-13.79% 20.39B
-0.83%-11.15%+169.70%+295.44% 15.72B
+2.92%+1.15%+43.64%+172.08% 14.07B
+0.17%-4.07%-9.71%+484.05% 14.03B
Average +1.30%-2.67%+28.61%+147.53% 27.24B
Weighted average by Cap. +1.49%+0.18%+36.10%+129.28%

Financials

2026 *2027 *
Net sales - 22.39M 19.5M 18.46M 16.77M 31.33M 2.14B 31.49M 220M 85.02M 1.09B 84.12M 82.25M 3.49B
Net income -94.04M -81.91M -77.52M -70.44M -132M -9.01B -132M -923M -357M -4.58B -353M -345M -14.65B -110M -95.66M -90.54M -82.26M -154M -10.52B -154M -1.08B -417M -5.35B -413M -403M -17.11B
Net Debt -150M -131M -124M -112M -210M -14.37B -211M -1.47B -569M -7.3B -563M -551M -23.37B -133M -116M -110M -99.61M -186M -12.74B -187M -1.31B -505M -6.47B -500M -489M -20.72B
Logo Compass Therapeutics, Inc.
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Employees
39
Date Price Change Volume
17/09/26 $1.850 +1.09% 2,494,841
16/09/26 $1.830 -1.08% 2,242,999
15/09/26 $1.850 -5.61% 2,440,059
14/09/26 $1.960 -2.00% 2,278,976
11/09/26 $2.000 -2.44% 4,828,614
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
1.830USD
Average target price
8.917USD
Spread / Average Target
+387.25%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CMPX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!